Abbott emphasises commitment to PAD with two new products

Abbott has emphasised its commitment to the treatment of peripheral artery disease (PAD) by introducing two new products into its line-up.

The FoxCross PTA Catheter and the HI-TORQUE Versacore .035 Guide Wire aim to give cardiac and vascular diseases a minimally-invasive solution, the company said.

The first, which is available in a range of diameters and lengths, is used to open peripheral arteries blocked by plaque.

According to Dr Joseph A R Cardenas, medical director of the cardiac catheterisation laboratory at the Yuma Regional Medical Centre in Arizona, US, highly-deliverable balloon dilation catheters are “key to successful patient outcomes”.

He said the FoxCross system provides “superb crossability” together with “impressive deflation”.

“If the balloon does not cross the blockage smoothly and reliably, the procedure can take longer and may be prone to complications, as well as additional costs,” he added.

Abbott’s UK operations employ about 2,000 people and the company’s operations are based in Maidenhead, Witney, Queenborough and Dartford.